November 1, 2023
12 p.m. ET
Duration: 30 minutes

Becker muscular dystrophy (BMD) is a serious dystrophinopathy. Declining function can begin at different ages, but once it begins, Becker patients are on an irreversible path to losing muscle and consequently, function.

For this third part of our series on Becker muscular dystrophy, we will discuss the following:

• A review and update of Edgewise Therapeutics’ clinical programs in Becker muscular dystrophy, including GRAND CANYON, a global pivotal trial.
• Putting the data into perspective for the community

Panelists

• Chair: John Wing, PhD, Executive Director Medical Affairs, Edgewise Therapeutics​
• Presenter: Joanne Donovan, MD, PhD, Chief Medical Officer, Edgewise​ Therapeutics

This webinar will be presented via Zoom. After registering, you will receive a confirmation email containing information about joining the webinar.

If you have questions or comments, contact mdapartners@mdausa.org.

For more educational programs and resources, please visit MDA Medical Education.

This Industry Update Webinar is sponsored by Edgewise Therapeutics. MDA is providing this resource as an educational opportunity for the neuromuscular disease community. This program is not sponsored, endorsed, or accredited by MDA.